Celsion Corporation (Nasdaq: CLSN) announced that interim data from its Phase I/II DIGNITY trial of ThermoDox® in Recurrent Chest Wall (RCW) Breast Cancer were presented at the poster session at the 2010 Breast Cancer Symposium. The abstract provided updated clinical results from the 40 mg/m2 dose cohort. Additionally the company announced that the 50 mg/m2 dose cohort has now completed enrollment. This DIGNITY study evaluates ThermoDox in combination with microwave hyperthermia in women with RCW Breast Cancer. The poster session was held October 1, 2010 at the Gaylord National Hotel in Suburban Washington, DC.
The abstract, titled "Phase I/II study evaluating the...
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry